---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011145"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:20:54.382058+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Altimmune reports Q2 2025 net loss of $22.1M; positive pemvidutide MASH data reinforces differentiation

## Summary
- Cash and investments $183.1M (up 39% from Dec 2024); net loss $22.1M ($0.27/sh) vs $24.6M ($0.35) Q2 2024.
- Pemvidutide achieved up to 59.1% MASH resolution without worsening fibrosis, up to 34.5% fibrosis improvement, and up to 6.2% weight loss at 24 weeks.
- New cT1 imaging data shows mean decreases of 145-148 ms (p<0.001), potentially class-leading in MASH trials.
- End-of-Phase 2 FDA meeting targeted for Q4 2025; full 48-week data expected Q4.
- Jerry Durso appointed Chairman; Mitchel Sayare remains director as part of board succession.

## SEC filing metadata
- accession: 0001558370-25-011145
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000155837025011145/0001558370-25-011145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000155837025011145/alt-20250812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011145
- JSON: https://secwatch.observer/filing/0001558370-25-011145.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.